Skip to main content

Latest stock market podcasts

From the helm: Argenica Therapeutics (ASX:AGN), Dr. Liz Dallimore, CEO & MD

Bell Direct
October 1, 2025

Join Bell Financial Group’s Senior Market Analyst Grady Wulff as she sat down with Dr. Liz Dallimore, CEO & MD of Argenica Therapeutics (ASX:AGN) to discuss the company’s lead drug candidate ARG-007, and its pathway to commercialisation to become the world’s first neuroprotective drug for the protection of brain cells post stroke or catastrophic brain injury.

In this interview, Liz covers:

  • (0:40) an overview of Argenica Therapeutics (ASX:AGN)
  • (1:28) details on ARG-007, including its mechanism in protecting brain cells after stroke
  • (4:59) expected runway, and potential need for additional financing pre-Phase 3
  • (8:42) other drug candidates in development within Argenica’s pipeline
  • (10:01) expected investor news flow over the next 12 months

Note: This interview was filmed on 24 September 2025.

Weekly Wrap 3 October

Bell Direct
October 3, 2025

Morning Bell 2 October

Bell Direct
October 2, 2025

Morning Bell 1 October

Bell Direct
October 1, 2025

Morning Bell 29 September

Bell Direct
September 29, 2025

Weekly Wrap 26 September

Bell Direct
September 26, 2025

Morning Bell 25 September

Bell Direct
September 25, 2025

Morning Bell 24 September

Bell Direct
September 24, 2025